Abstract
Objective: To evaluate the impact of statins on carotid restenosis (CR) >50% and future cardiovascular events (CVE), in patients undergoing carotid endarterectomy (CEA).
Methods: 570 consecutive patients (656 CEAs) operated between 1990 and 2009, were included in this retrospective study. The study cohort was followed for an average of 82 months (median 80, range 12- 180 months). Endpoints were the development of CR >50%, the occurrence of CVE (myocardial infarction, stroke) and overall mortality. Kaplan-Meier curves and Cox regression models were used to assess outcomes.
Results: 92 restenosis events were recorded. Freedom from restenosis >50% at 5, 10 and 15 years of follow-up was 92, 82 and 69%, respectively. Compared with statin-receivers, statin-free patients had a significantly higher 15-year restenosis rate (41 vs 10%; P = .001), a significantly higher CVE rate (49 vs 14%; P = .001) and a significantly higher mortality rate (24 vs 18%; P = .034). Adjusting for other covariates statins were independently associated with lower restenosis rate (hazard ratio [HR], 0.52; 95% CI, 0.31-0.88; P= .016), cardiovascular events (HR, 0.40; 95% CI, 0.26-0.61; P < 0.001) and long-term mortality (HR, 0.56; 95% CI, 0.33-0.95; P = .032).
Conclusion: Statins not only reduce cardiovascular events and mortality but may also have an important effect on the anatomic durability of CEA. These data support the use of statins in patients with carotid stenosis undergoing CEA.
Keywords: Carotid endarterectomy, restenosis, mortality, echolucent plaque, statins.
Current Vascular Pharmacology
Title:Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Volume: 13 Issue: 2
Author(s): Efthymios D. Avgerinos, John D. Kakisis, Konstantinos G. Moulakakis, Triantafillos G. Giannakopoulos, George Sfyroeras, Constantinos N. Antonopoulos, Nikolaos P. Kadoglou and Christos D. Liapi
Affiliation:
Keywords: Carotid endarterectomy, restenosis, mortality, echolucent plaque, statins.
Abstract: Objective: To evaluate the impact of statins on carotid restenosis (CR) >50% and future cardiovascular events (CVE), in patients undergoing carotid endarterectomy (CEA).
Methods: 570 consecutive patients (656 CEAs) operated between 1990 and 2009, were included in this retrospective study. The study cohort was followed for an average of 82 months (median 80, range 12- 180 months). Endpoints were the development of CR >50%, the occurrence of CVE (myocardial infarction, stroke) and overall mortality. Kaplan-Meier curves and Cox regression models were used to assess outcomes.
Results: 92 restenosis events were recorded. Freedom from restenosis >50% at 5, 10 and 15 years of follow-up was 92, 82 and 69%, respectively. Compared with statin-receivers, statin-free patients had a significantly higher 15-year restenosis rate (41 vs 10%; P = .001), a significantly higher CVE rate (49 vs 14%; P = .001) and a significantly higher mortality rate (24 vs 18%; P = .034). Adjusting for other covariates statins were independently associated with lower restenosis rate (hazard ratio [HR], 0.52; 95% CI, 0.31-0.88; P= .016), cardiovascular events (HR, 0.40; 95% CI, 0.26-0.61; P < 0.001) and long-term mortality (HR, 0.56; 95% CI, 0.33-0.95; P = .032).
Conclusion: Statins not only reduce cardiovascular events and mortality but may also have an important effect on the anatomic durability of CEA. These data support the use of statins in patients with carotid stenosis undergoing CEA.
Export Options
About this article
Cite this article as:
Avgerinos D. Efthymios, Kakisis D. John, Moulakakis G. Konstantinos, Giannakopoulos G. Triantafillos, Sfyroeras George, Antonopoulos N. Constantinos, Kadoglou P. Nikolaos and Liapi D. Christos, Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/15701611113119990130
DOI https://dx.doi.org/10.2174/15701611113119990130 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology Antifungal Activity of Condensed Tannins from Stryphnodendron adstringens: Effect on Candida tropicalis Growth and Adhesion Properties
Current Pharmaceutical Biotechnology Effects of Senna didymobotrya Root Extract and Compounds on Tritoninduced Hyperlipidaemic Rats and Differentiation of 3T3-Li Preadipocytes
The Natural Products Journal A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Factors Influencing Adherence Among Youth with Type-1-Diabetes Mellitus - The Hungarian Case
Current Diabetes Reviews Editorial (Thematic Issue: Current Updates on Association Between Alzheimer’s Disease and Type 2 Diabetes Mellitus - Volume II)
CNS & Neurological Disorders - Drug Targets The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Diabetes Mellitus and Renal Function: Current Medical Research and Opinion
Current Diabetes Reviews Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature
Current Cardiology Reviews Association Between Seizures and Diabetes Mellitus: A Comprehensive Review of Literature
Current Diabetes Reviews Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Development of Novel Glitazones as Antidiabetic Agents: Molecular Design, Synthesis, Evaluation of Glucose Uptake Activity and SAR Studies
Letters in Drug Design & Discovery Suppression of TLR Signaling by Targeting TIR domain-Containing Proteins
Current Protein & Peptide Science